JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B‐Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation

Background Canine diffuse large B‐cell lymphoma (DLBCL) is a common and aggressive hematologic malignancy. The lack of conventional therapies with sustainable efficacy warrants further investigation of novel therapeutics. The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways play important roles in the pathogenesis of hematologic malignancies in humans including DLBCLs. AZD1480 and CYT387 are novel JAK1/2 inhibitors that have been used in clinical trials for treating various hematologic cancers in humans. No studies have characterized the antitumor effects of JAK inhibitors on DLBCL in dogs. Hypothesis/Objectives We hypothesize that JAK1/2 inhibitors AZD1480 and CYT387 can effectively inhibit growth of canine DLBCL in vitro. We aim to assess the antitumor activity of AZD1480 and CYT387 in canine DLBCL and to determine the underlying mechanisms of action. Methods In vitro study of canine lymphoma cell growth, proliferation, and apoptosis by viability, proliferation and apoptosis assays. Results A significant decrease in viable canine lymphoma cells was observed after AZD1480 and CYT387 treatments. In addition, AZD1480 and CYT387 treatment resulted in decreased lymphoma cell proliferation and increased early apoptosis. Conclusion and Clinical Importance AZD1480 and CYT387 inhibit canine lymphoma cell growth in a dose‐dependent manner. Our findings justify further phase I/II clinical investigations of the safety and efficacy of JAK1/2 inhibitors in canine DLBCL and suggest new opportunities for novel anticancer therapies.

[1]  Z. Lu,et al.  Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma. , 2018, Veterinary and comparative oncology.

[2]  L. Staudt,et al.  Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma , 2016, Proceedings of the National Academy of Sciences.

[3]  M. Linden,et al.  The Comparative Diagnostic Features of Canine and Human Lymphoma , 2016, Veterinary sciences.

[4]  H. Kantarjian,et al.  A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. , 2015, Leukemia research.

[5]  M. Stegemann,et al.  Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia , 2014, Veterinary dermatology.

[6]  E. Ranheim,et al.  Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. , 2014, The Journal of clinical investigation.

[7]  R. Jove,et al.  Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells. , 2014, Blood.

[8]  A. Rashid,et al.  Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma. , 2014, Human pathology.

[9]  R. Levine,et al.  Molecular Pathways Molecular Pathways : Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors , 2014 .

[10]  A. Gonzales,et al.  Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy , 2014, Journal of veterinary pharmacology and therapeutics.

[11]  J. Tena,et al.  A blinded, randomized, placebo‐controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client‐owned dogs with atopic dermatitis , 2013, Veterinary dermatology.

[12]  E. Plimack,et al.  AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. , 2013, The oncologist.

[13]  W. Vainchenker,et al.  JAK/STAT signaling in hematological malignancies , 2013, Oncogene.

[14]  R. Laborde,et al.  Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis , 2013, Leukemia.

[15]  C. Thiele,et al.  Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo , 2013, Oncotarget.

[16]  A. Quintás-Cardama,et al.  Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance , 2013, Clinical Cancer Research.

[17]  S. Willenbrock,et al.  Authentication of Primordial Characteristics of the CLBL-1 Cell Line Prove the Integrity of a Canine B-Cell Lymphoma in a Murine In Vivo Model , 2012, PloS one.

[18]  C. Burns,et al.  The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells , 2011, Leukemia.

[19]  R. Figlin,et al.  Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. , 2011, Cancer research.

[20]  A. Tefferi,et al.  JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. , 2011, Blood reviews.

[21]  R. Jove,et al.  The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival , 2011, Leukemia.

[22]  A. Younes.  Beyond chemotherapy: new agents for targeted treatment of lymphoma , 2011, Nature Reviews Clinical Oncology.

[23]  Jon Read,et al.  Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway. , 2011, Journal of medicinal chemistry.

[24]  W. Gerner,et al.  Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. , 2010, Leukemia research.

[25]  B. Druker,et al.  CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. , 2010, Blood.

[26]  Hua Yu,et al.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. , 2009, Cancer cell.

[27]  Tao Wang,et al.  Effects of the JAK2 Inhibitor, AZ960, on Pim/BAD/BCL-xL Survival Signaling in the Human JAK2 V617F Cell Line SET-2* , 2008, Journal of Biological Chemistry.

[28]  G. Cattoretti,et al.  Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. , 2007, Blood.

[29]  T. McDonnell,et al.  Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma , 2004, Oncogene.

[30]  G. Feldman,et al.  Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. , 2003, Blood.

[31]  J. Turkson,et al.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. , 2001, The Journal of clinical investigation.

[32]  B. Bonavida,et al.  Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.